|Shanghai Institute ofImmunology|
ShanghaiInstitute of Immunology (SII) was established in 1979 as the firstresearch institute focused on Immunology in China. With the rapideconomic development and the drive to pursue scientific excellencein China in recent years, SII has evolved into a modern institutionwith the infrastructure for cutting-edge research and vigoroustraining of graduate students and postdoctoral fellows. Theresearch at SII encompasses various aspects of immunology, frombasic research to understand the immune system to translationalresearch focusing on developing novel immunotherapies to preventand treat infectious diseases, autoimmune diseases, andcancers. SII has implemented the Principal Investigator (PI)management system conducive for independent research and productivecollaborations. Currently, the institute has sevenlaboratories studying immune regulation, immunity to infection,autoimmunity, transplantation, and cancer immunology. We areentering an expansional phase and are in the process of recruitingnew PIs at the rate of 2-3 per year. The quality and scope of ourresearch is further strengthened and broadened by extensive jointresearch programs with clinicians at affiliated hospitals and byongoing collaborations with groups within China and abroad. In support of these collaborative programs, long-term collaboratorsare appointed as Adjutant Members of the institute with specialfund to support the collaborative pilot projects. Our technologycore facility is equipped with state-of-the-art equipment requiredby modern immunological research. The institute is well supportedby a special fund from the Shanghai City municipal government, byfund from the “985” and “211” projects of JiaoTong UniversitySchool of Medicine, and by grants from various funding sources(including “975” “863” and NSFC) to individual PIs. SII is the hometo the editorial office of the journal, Modern Immunology, and tothe WHO Collaborative Center for Immunogenetics andImmunopathology.
Building5,280 South Chongqing Road, Shanghai, P.R. China
Bing Su, Ph.D., Professor
Director, Shanghai Institute of Immunology
Chairman, Department of Immunobiology andMicrobiology
Expert of “1000 Plan” (Recruitment Program of GlobalExperts)
Changjiang Scholar Chair Professor
Shanghai Jiao Tong University Chair Professor
Associate Professor with Tenure, Department ofImmunobiology and The Vascular Biology and Therapeutic Program,Yale University School of Medicine
1984 Peking University, Beijing, China, B.S.
1987 Yale University, New Haven, Connecticut, M.Ph.
1991 Yale University, New Haven, Connecticut, Ph.D.
1991-1995 Postdoctoral Fellow, University of California at San Diego,La Jolla, CA
1995-2006 AssistantProfessor, Associate Professor (Tenure) and Professor (Tenure),Immunology Department, The University of Texas, M D Anderson CancerCenter, Houston, TX
1995- Assistant, Associate, and Professor,Graduate School of Biological Science, The University of TexasHealth Science Center at Houston, Houston, TX
2006- Associate Professor, Associate Professor (Tenure),Department of Immunobiology and Vascular Biology and TherapeuticProgram, Yale University School of Medicine, New Haven,CT
2008- Adjunct Professor, Xiang-Ya Hospital, Central SouthUniversity, Changsha, China
2012- Chair Professor, Shanghai Jiao Tong University, Shanghai,China
2012- Professor and Director, Shanghai Institute of Immunology,Shanghai Jiao Tong University School of Medicine, Shanghai,China
2013- Chairman, Department of Immunobiology and Microbiology,Shanghai Jiao Tong University School of Medicine, Shanghai,China
Dr. Bing Su’s laboratory is interested in the roles ofthe mechanistic target of rapamycine (mTOR) pathway and themitogen-activated protein kinase (MAPK) cascades in immune andmetabolic regulation during intestine homeostasis, autoimmunity,inflammation, and cancer development.
1985 CUSBEA (China and US Biochemistry and Molecular Biol. ExamApplication) Award
1985 Sterling Prize Fellowship,Yale University, Graduate School
1992 The Irvington InstitutePostdoctoral Fellowship Award, Class 1995, New York
1995 Special Fellowship Award,Leukemia Society of America
2009 Changjiang Scholar Chair Professorship, Ministry of Education ofChina
2012 Expert of “1000 Plan” of Shanghai Municipal Government
2012 Expert of “1000 Plan” (Recruitment Program of Global Experts),Central Government
1. FanZhang, Adam Lazorchak, Dou Liu, Fanping Chen, Su B. Inhibition ofthe mTORC2 and chaperone pathways to treat leukemia. Blood. 2012Jun 21;119(25):6080-8.
2. XingChang, Fang Liu, Xiaofang Wang, and Su B. MEKK2 and MEKK3 regulateTGF-b-mediated helper T cell differentiation. Immunity. 34:201-212, 2011.
3. Adam SLazorchak, Dou Liu, Valeria Facchinetti, Annarita Di Lorenzo,William C Sessa, David G Schatz & Su B. Sin1 suppresses rag1/2and il7r gene expression through Akt2 in B cells. Mol. Cell. 39:433-443, 2010.PMCID2957800
4. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q,Qin J, and Su B. SIN1/MIP1 maintains rictor-mTOR complex integrityand regulates Akt phosphorylation and substrate specificity. Cell,127(1):125-37, 2006.
5. Qiaojia Hunag, Jianhua Yang, Yong Lin, Christopher Walker, ZenggangLiu, and Su B. Differential regulation of interleukin-1 receptorand Toll-like receptor (TLR) signaling by MEKK3. Nature Immunology5(1):98-103, 2004.
6. YangJ., Lin Y., Guo Z, Cheng J, Huang H, Liao W, Chen Z, Liu Z, SuB. The essential role of MEKK3 in TNF-induced NF-kBactivation. Nature Immunology 2:620-624, 2001.
7. YangJ, Boerm M, McCarty M, Bucana C, Fidler J, Zhuang Y, and SuB. Essential role of MEKK3 in early embryonic cardiovasculardevelopment. Nature Genetics 24:309-313, 2000